Akademik Veri Yönetim Sistemi
Final Meeting PlasTHER COST Action, Barcelona, İspanya, 17 - 20 Haziran 2025, ss.82, (Özet Bildiri)
Cold Atmospheric Plasma: ceRNA Network and Paraptosis in Prostate Cancer İrem Coşkuntan a, Neslihan Abacı b a,b Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that evolves through genomic changes, causing resistance to androgen deprivation therapy (ADT). While second-generation androgen receptor (AR) antagonists are used, long-term treatment can disrupt oncogenic pathways and resistance to apoptosis. Understanding ADT desensitization is crucial for developing better CRPC therapies 1. Cold atmospheric plasma (CAP), a redox modulation tool, shows promise in treatment of various cancers by selectively triggering programmed cell death pathways such as apoptosis; however, its clinical use as an oncotherapy is limited by inconsistent results across tumor types, and CAP device configurations 2,3. Paraptosis, a non-apoptotic cell death mechanism, involves ER and mitochondrial swelling and is triggered by stress factors like ROS and ion imbalance 4. Combining apoptosis and paraptosis could improve cancer treatment 5; nevertheless, it is still uncertain whether CAP therapy can induce paraptosis. Moreover, the competing endogenous RNAs (ceRNAs) hypothesis has defined a new RNA interaction network by expanding the roles of both messenger RNA (mRNA) and noncoding RNAs (ncRNAs) in regulating gene expression 6.Variable treatment responses in cancer therapy may be mediated by functional interactions of unidentified ceRNA networks, and elucidation of these networks may contribute to the development of cancer treatment strategies. In this study, bioinformatics analysis approaches will be used to identify overexpressed genes in CRPC data from GEO and TCGA datasets and construct a ceRNA network. After confirming hub gene expression in CRPC cell lines, the anti-tumor effects of CAP treatment will be investigated. Functional analysis will be conducted to evaluate whether CAP induces paraptosis via ROS production, providing potential targets for CRPC treatment strategies. Acknowledgements: This abstract is based upon work from COST Action CA20114 PlasTHER “Therapeutical Applications of Cold Plasmas”, supported by COST (European Cooperation in Science and Technology). References 1. Celada SI, Li G, Celada LJ, et al., Sci Signal, vol. 17,867 (2024), eadk4122. DOI:10.1126/scisignal.adk4122 2. Živanić M, Espona-Noguera A, Lin A, Canal C., Adv Sci (Weinh), vol. 10,8 (2023), e2205803. DOI:10.1002/advs.202205803 3. Dai X, Wu J, Lu L, Chen Y., Biomol Ther (Seoul), vol. 31,5 (2023), 496-514. DOI:10.4062/biomolther.2023.027 4. Chen F, Tang H, Cai X, et al., Cancer Gene Ther, vol. 31,3 (2024), 349-363. DOI:10.1038/s41417-023-00722y 5. Yang MH, Son NT, Bastos JK, et al., Arch Biochem Biophys, vol. 766 (2025), 110331. DOI:10.1016/j.abb.2025.110331 6. Ala U. Cells, vol. 9,7 (2020), 1574. DOI:10.3390/cells9071574